CDSCO Panel Withholds Nod for Syngene's Pegfilgrastim Trial, Seeks Additional Data

Published On 2025-07-31 08:31 GMT   |   Update On 2025-07-31 08:31 GMT
Advertisement

New Delhi: The Subject Expert Committee under the Central Drugs Standard Control Organisation (CDSCO) has directed Syngene International Limited to submit additional data before it proceeds further with evaluating the firm's proposal to conduct a Phase I clinical trial comparing Pegfilgrastim administered through an On-Body Injector (OBI) kit and a prefilled syringe (PFS).

The firm had presented its application for a Phase I study titled: “A Randomized, Open-label, Single-dose, Three-period, Two-treatment, Three-sequence, Partial Replicate Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fulphila OBI kit and Fulphila PFS (pegfilgrastim) for manual use in Normal Healthy Male Volunteers.” This was submitted under protocol number SYNCD-052-24/BIO-PEGFIL-102 Version 2.0 dated 5 June 2025.

Pegfilgrastim is a long-acting form of recombinant human granulocyte colony-stimulating factor (G-CSF), used to prevent febrile neutropenia in cancer patients undergoing chemotherapy. It reduces the duration of neutropenia and the risk of infection by stimulating the bone marrow to increase neutrophil production. The PFS and OBI formats are designed to improve delivery efficiency and patient convenience.

Advertisement

During the SEC’s 23rd Oncology meeting held on 17 July 2025 at CDSCO headquarters, the expert panel reviewed the proposal and made several key observations.

The committee noted that the proposed Pegfilgrastim in prefilled syringes (PFS) is already approved in more than 45 countries, including the United States, European Union, Canada, Australia, and Switzerland. Furthermore, the panel acknowledged that the current submission represents a line extension approval in both the EU and the USA.

However, before approving the study, the committee has asked the firm to submit additional data, specifically:

In-use stability data of the drug when used with the OBI kit

Data on the functionality and performance evaluation of the OBI device

“Accordingly, the firm shall submit the above information for further evaluation by the SEC.”

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News